Hemodiafiltration With Endogenous Reinfusion on Uremic Toxins Clearance of Maintenance Hemodialysis Patients
Study Details
Study Description
Brief Summary
1.1Primary Objective To evaluate the clearance rate of uremic toxin β2-microglobulin (β2-MG), indoxyl sulfate and λ-free light chain (λFLC) by HFR.
1.2Secondary Objectives 1.1.1 To evaluate the clearance of low molecular weight uremic toxin urea (spKt/V, URR).
1.1.2 To evaluate the clearance of other middle molecules and macromolecular uremic toxins, including α1-microglobulin (α1-MG), κ-free light chain (κFLC), homocysteine (Hcy), interleukin-6 (IL-6), p-cresol, YKL-40, complement factor D (CFD), leptin, hippuric acid, trimethylamine oxide (TMAO), asymmetric dimethylarginine (ADMA), tumor necrosis factor-α (TNF- α), myoglobin, fibroblast growth factor 23 (FGF23) and intact parathyroid hormone (iPTH).
1.1.3 To evaluate the clearance of serum albumin, branched chain amino acids and vitamins A, C, E.
1.1.4 To evaluate the comfort of HFR treatment for MHD patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: HFR treatment patient received HFR treatment |
Other: HFR
patient received HFR treatment
|
Outcome Measures
Primary Outcome Measures
- β2-microglobulin (β2-MG), indoxyl sulfate and λ-free light chain (λFLC) [1 day]
The concentrations of β2-microglobulin (β2-MG), indoxyl sulfate and λ-free light chain (λFLC) were measured before and after HFR
Secondary Outcome Measures
- Single-compartment urea clearance index (spKt/V), Urea Reduction Ratio [1 day]
Calculate spKt/V and Urea Reduction Ratio.
- other middle molecules and macromolecular uremic including α1-MG, κFLC, Hcy, IL-6, p-cresol, YKL-40, CFD, leptin, hippuric acid, TMAO, ADMA, TNF-α, myoglobin, FGF23 and iPTH [1 day]
The concentrations of other middle molecules and macromolecular uremic were measured before and after HFR
- serum albumin, branched chain amino acids and vitamins A, C, E [1 day]
The concentrations of serum albumin, branched chain amino acids and vitamins A, C, E before and after HFR
- the comfort of HFR treatment [1 day]
The dialysis comfort score was used for evaluation
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18-75 years old, regardless of gender.
-
MHD for at least 3 months, and blood purification treatment for 3 times per week.
-
The vascular access is autogenous arteriovenous fistula or artificial blood vessels，with a blood flow ≥200mL/min.
-
spKt/V≥1.2.
-
Patients who signed the informed consent form (ICF) voluntarily.
Exclusion Criteria:
-
Patients who have participated in other interventional clinical trials within a month.
-
Pregnant or lactating women.
-
Patients of NYHA class IV or occurred acute coronary syndrome or myocardial infarction in 3 months before the start of the study.
-
Patients with active hemorrhage in 2 weeks (e.g., cerebral hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage, etc.).
-
Patients with unstable blood pressure (pre-dialysis systolic blood pressure ≥180 or ≤90mmHg, pre-dialysis diastolic blood pressure ≥100 or ≤60mmHg), severe anemia (hemoglobin ≤60g/L), and high risk of blood coagulation (e.g., albumin ≤25g/L or hemoglobin ≥140g/L).
-
Patients with severe infection (the level of hypersensitive C-reactive protein(hsCRP) ≥ 10×upper limit of normal).
-
Patients with a history of drug addiction or severe mental disorders.
-
Other conditions in which the investigators reject patients to participate in this study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- RenJi Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- KY2023-077